Drug Trial Radar · NCT06540963
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
98
Planned (sponsor's estimate)
Start
Dec 6, 2024
Primary completion
Dec 1, 2030
Study completion Dec 1, 2035
Sponsor
- Lead sponsor
- Giselle ShollerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). Naxitamab is FDA approved for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy, it may not be approved in the type of disease used in this study. The goals of this part of the study are: * Test the safety and tolerability of tipifarnib in combination with naxitimab in participants with cancer * To determine the activity of study treatments chosen based on: * How each participant responds to the study treatment * How long a participant lives without their disease returning/progressing
Conditions
- Neuroblastoma
Interventions
TipifarnibDrug
Tablet
NaxitamabDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Overall Response Rate (ORR) of Participants using INSS ResponseTime frame: 6 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Connecticut Children's Hospital
Hartford, Connecticut · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Recruiting
Arnold Palmer Hospital for Children
Orlando, Florida · Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii · Recruiting
Cardinal Glennon Children's Medical Center
St Louis, Missouri · Recruiting
Duke University
Durham, North Carolina · Recruiting
Randall Children's Hospital
Portland, Oregon · Recruiting
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Monroe Carrell Jr. Children's Hospital at Vanderbilt
Nashville, Tennessee · Recruiting
Dell Children's Blood and Cancer Center
Austin, Texas · Recruiting
Children's Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.